UnitedHealthcare Starts Coverage Of Myriad Genetics’ Genomic Depression Test

Genomics testing company Myriad Genetics is building on its growing momentum in the marketplace with a positive policy decision from UnitedHealthcare for its pharmacogenomic test for depression. Salt Lake City-based Myriad Genetics’ GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression. The information can be used by clinicians to more effectively target treatments to help ease symptoms.

UnitedHealthcare made its decision on the back of the company’s recently published GUIDED study which found that the GeneSight test was able to drive improvements in remission among individuals with depression who . . .